One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders

One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders

Purpose: A sub-population of patients with diabetic macular edema (DME) responds less effectively to off-label use of Bevacizumab. Approval of Aflibercept for DME has offered Bevacizumab nonresponders an alternative therapeutic option. Herein, we investigate the anatomical and functional changes ass...

Full description

Bibliographic Details
Main Authors: Ali Salimi, Natalia Vila, Milad Modabber, Michael Kapusta
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Indian Journal of Ophthalmology
Subjects:
aflibercept
anti-vegf
bevacizumab
diabetic macular edema
refractory
Online Access:http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=2;spage=360;epage=367;aulast=Salimi

Internet

http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=2;spage=360;epage=367;aulast=Salimi

Similar Items